ADMA and NOS regulation in chronic renal disease: beyond the old rivalry for l-arginine

Kidney Int. 2012 Apr;81(8):722-4. doi: 10.1038/ki.2011.496.


Chronic kidney disease is associated with increased levels of assymetric N(G),N(G)-dimethylarginine (ADMA), which is predictive of increased mortality and cardiovascular disease. ADMA induces endothelial dysfunction through competitive inhibition of the endothelial nitric oxide (eNOS) substrate L-arginine. Kajimoto et al. show that ADMA may also reduce nitric oxide production via decreased eNOS phosphorylation; this effect is mediated by the MAPK pathway and can be reversed in vivo by increased catabolism of ADMA through dimethylarginine dimethylaminohydrolase-1 overexpression.

Publication types

  • Comment

MeSH terms

  • Animals
  • Arginine / analogs & derivatives*
  • Arginine / blood
  • Humans
  • Male
  • Nitric Oxide Synthase Type III / antagonists & inhibitors*
  • Renal Insufficiency, Chronic / physiopathology*


  • N,N-dimethylarginine
  • Arginine
  • Nitric Oxide Synthase Type III
  • Nos3 protein, mouse